» Articles » PMID: 16647145

Construction and Characterization of Bacterial Artificial Chromosomes Containing HSV-1 Strains 17 and KOS

Overview
Journal J Virol Methods
Specialty Microbiology
Date 2006 May 2
PMID 16647145
Citations 94
Authors
Affiliations
Soon will be listed here.
Abstract

Bacterial artificial chromosomes (BACs) were constructed containing full-length, infectious DNA of HSV-1 strains 17 and KOS. To generate BACs without altering viral genes, sequences required for selection and propagation of the BAC were placed between the U(L)37 and U(L)38 genes, and flanked by LoxP sites. The system was tested by studying multiple properties of these HSV-1 BAC constructs in vitro and in vivo following propagation in bacteria, virus reconstitution from HSV-BAC DNA in eukaryotic cells, and Cre-recombinase-mediated excision of the BAC backbone. Based on in vitro growth in mouse embryo fibroblasts and in vivo growth in mouse corneas and trigeminal ganglia, the strain KOS BAC-derived virus behaved similarly to wild-type. Small changes in neurovirulence were, however, observed. The strain 17 BAC-derived virus exhibited modest decreases in growth and virulence compared to wild-type. Modest differences were observed in reactivation from latency with both strain KOS and 17 BAC-derived viruses. In addition, the system was further validated by performing mutagenesis of the BACs by allelic exchange in E. coli. These BACs are suitable for the rapid generation of recombinant viruses for pathogenesis and other studies, but as with all mutagenesis systems, care must be taken in their construction and repair.

Citing Articles

Viral gene drive spread during herpes simplex virus 1 infection in mice.

Walter M, Haick A, Riley R, Massa P, Strongin D, Klouser L Nat Commun. 2024; 15(1):8161.

PMID: 39289368 PMC: 11408514. DOI: 10.1038/s41467-024-52395-2.


Development of a novel, high-efficacy oncolytic herpes simplex virus type 1 platform equipped with two distinct retargeting modalities.

Joo H, Baek H, Ahn C, Park E, Lee Y, Lee S Mol Ther Oncol. 2024; 32(1):200778.

PMID: 38596302 PMC: 10941007. DOI: 10.1016/j.omton.2024.200778.


Oncolytic herpes simplex viruses designed for targeted treatment of EGFR-bearing tumors.

Ingusci S, Hall B, Cohen J, Glorioso J Mol Ther Oncol. 2024; 32(1):200761.

PMID: 38596286 PMC: 10869753. DOI: 10.1016/j.omton.2024.200761.


Combined effect of the pro-apoptotic rhTRAIL protein and HSV-1 virus in head and neck cancer cell lines.

Bravo Perina L, Gomes I, Alcantara Pelloso A, Silva V, Arantes L, Melendez M Sci Rep. 2023; 13(1):18023.

PMID: 37865660 PMC: 10590400. DOI: 10.1038/s41598-023-44888-9.


CRISPR-Cas9 Expressed in Stably Transduced Cell Lines Promotes Recombination and Selects for Herpes Simplex Virus Recombinants.

Oh H, Diaz F, Zhou C, Carpenter N, Knipe D Curr Res Virol Sci. 2022; 3.

PMID: 36330462 PMC: 9629518. DOI: 10.1016/j.crviro.2022.100023.